ATE434040T1 - MULTI-CHAIN EUKARYONTIC DISPLAY VECTORS AND USES THEREOF - Google Patents

MULTI-CHAIN EUKARYONTIC DISPLAY VECTORS AND USES THEREOF

Info

Publication number
ATE434040T1
ATE434040T1 AT02766425T AT02766425T ATE434040T1 AT E434040 T1 ATE434040 T1 AT E434040T1 AT 02766425 T AT02766425 T AT 02766425T AT 02766425 T AT02766425 T AT 02766425T AT E434040 T1 ATE434040 T1 AT E434040T1
Authority
AT
Austria
Prior art keywords
chain
chain polypeptide
host cell
vector
display
Prior art date
Application number
AT02766425T
Other languages
German (de)
Inventor
Simon Hufton
Hendricus Hoogenboom
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23271723&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE434040(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dyax Corp filed Critical Dyax Corp
Application granted granted Critical
Publication of ATE434040T1 publication Critical patent/ATE434040T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2795/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Image Generation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Control Of Indicators Other Than Cathode Ray Tubes (AREA)
  • Error Detection And Correction (AREA)

Abstract

A eukaryotic expression vector capable of displaying a multi-chain polypeptide on the surface of a host cell is provided, such that the biological activity the multi-chain polypeptide is exhibited at the surface of the host cell. Such a vector allows for the display of complex biologically active polypeptides, e.g., biologically active multi-chain polypeptides such as immunoglobulin Fab fragments. The present invention describes and enables the successful display of a multi-chain polypeptide on the surface of a eukaryotic host cell. Preferred vectors are described for expressing the chains of a multi-chain polypeptide in a host cell separately and independently (e.g., under separate vector control elements, and/or on separate expression vectors, thus forming a matched vector set). The use of such matched vector sets provides flexibility and versatility in the generation of eukaryotic display libraries, for example the ability to generate and to display multi-chain polypeptides by combining and recombining vectors that express variegations of the individual chains of a multi-chain polypeptide. Entire repertoires of novel chain combinations can be devised using such vector sets.
AT02766425T 2001-10-01 2002-09-30 MULTI-CHAIN EUKARYONTIC DISPLAY VECTORS AND USES THEREOF ATE434040T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32632001P 2001-10-01 2001-10-01
PCT/US2002/031113 WO2003029456A1 (en) 2001-10-01 2002-09-30 Multi-chain eukaryotic display vectors and uses thereof

Publications (1)

Publication Number Publication Date
ATE434040T1 true ATE434040T1 (en) 2009-07-15

Family

ID=23271723

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02766425T ATE434040T1 (en) 2001-10-01 2002-09-30 MULTI-CHAIN EUKARYONTIC DISPLAY VECTORS AND USES THEREOF

Country Status (11)

Country Link
US (10) US20030186374A1 (en)
EP (2) EP2093286B1 (en)
JP (2) JP4578098B2 (en)
AT (1) ATE434040T1 (en)
AU (2) AU2002330162B2 (en)
CA (1) CA2462113C (en)
DE (1) DE60232672D1 (en)
DK (2) DK1438400T3 (en)
ES (2) ES2405551T3 (en)
PT (1) PT1438400E (en)
WO (1) WO2003029456A1 (en)

Families Citing this family (196)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696251B1 (en) 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6759243B2 (en) * 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
US20050196755A1 (en) * 2000-11-17 2005-09-08 Maurice Zauderer In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
WO2002102855A2 (en) * 2000-11-17 2002-12-27 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
EP1355666B1 (en) 2000-12-22 2012-06-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Use of repulsive guidance molecule (RGM) and its modulators
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
AU2002338446A1 (en) * 2001-01-23 2002-11-05 University Of Rochester Medical Center Methods of producing or identifying intrabodies in eukaryotic cells
ES2405551T3 (en) 2001-10-01 2013-05-31 Dyax Corporation Multicatenary eukaryotic presentation vectors and uses thereof
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
EP2290107A1 (en) 2003-01-07 2011-03-02 Dyax Corporation Kunitz domain library
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
JP4994038B2 (en) * 2003-10-22 2012-08-08 ケック グラジュエイト インスティチュート Method for the synthesis of heteromultimeric polypeptides in yeast using the haploid conjugation method
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
CA2550933A1 (en) * 2003-12-22 2005-07-14 Amgen Inc. Methods for identifying functional antibodies
RS50830B (en) 2005-01-05 2010-08-31 F-Star Biotechnologische Forschungs-Und Entwicklungsges M.B.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
CN103146708A (en) * 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40 binding proteins
CA2618482C (en) 2005-08-19 2014-10-07 Abbott Laboratories Dual variable domain immunoglobin and uses thereof
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2500354A3 (en) 2005-08-19 2012-10-24 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1928905B1 (en) 2005-09-30 2015-04-15 AbbVie Deutschland GmbH & Co KG Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
US7790655B2 (en) * 2005-10-14 2010-09-07 Medimmune, Llc Cell display of antibody libraries
EP1954718B1 (en) 2005-11-30 2014-09-03 AbbVie Inc. Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
KR20140087058A (en) 2005-11-30 2014-07-08 애브비 인코포레이티드 Monoclonal antibodies against amyloid beta protein and uses thereof
US7845537B2 (en) 2006-01-31 2010-12-07 Ethicon Endo-Surgery, Inc. Surgical instrument having recording capabilities
US8992422B2 (en) 2006-03-23 2015-03-31 Ethicon Endo-Surgery, Inc. Robotically-controlled endoscopic accessory channel
US20090082221A1 (en) * 2006-05-04 2009-03-26 Kevin Caili Wang Cross-Species and Multi-Species Display Systems
TWI369402B (en) 2006-07-05 2012-08-01 Catalyst Biosciences Inc Protease screening methods and proteases identified thereby
AT503889B1 (en) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F MULTIVALENT IMMUNE LOBULINE
PT3339445T (en) * 2006-09-08 2020-09-01 Abbvie Bahamas Ltd Interleukin -13 binding proteins
WO2008070367A2 (en) 2006-11-01 2008-06-12 Facet Biotech Corporation Mammalian cell-based immunoglobulin display libraries
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20110076752A1 (en) * 2007-02-09 2011-03-31 Medimmune, Llc Antibody library display by yeast cell plasma membrane
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
EP2617827A1 (en) 2007-03-26 2013-07-24 Celexion, LLC Method for displaying engineered proteins on a cell surface
DK2134853T3 (en) 2007-04-03 2018-10-08 Oxyrane Uk Ltd Glycosylation of molecules
PE20090329A1 (en) * 2007-05-30 2009-03-27 Abbott Lab HUMANIZED ANTIBODIES AGAINST GLOBULOMER AB (20-42) AND ITS USES
US20090232801A1 (en) * 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
ES2975748T3 (en) 2007-06-26 2024-07-12 F Star Therapeutics Ltd Presentation of bonding agents
DK2190987T3 (en) 2007-08-21 2013-02-18 Morphosys Ag Methods for forming disulfide bonds
US8691730B2 (en) 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) * 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US7947495B2 (en) 2007-11-01 2011-05-24 Abbott Biotherapeutics Corp. Immunoglobulin display vectors
US8637435B2 (en) * 2007-11-16 2014-01-28 Merck Sharp & Dohme Corp. Eukaryotic cell display systems
US8716437B2 (en) 2007-12-07 2014-05-06 Steven A. Goldstein Identification of toxin ligands
CA2711806A1 (en) * 2008-01-11 2009-07-16 Morphosys Ag Display vectors and methods and uses thereof
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
EP2263089B1 (en) * 2008-03-03 2015-01-28 GlycoFi, Inc. Surface display of recombinant proteins in lower eukaryotes
EP2098536A1 (en) 2008-03-05 2009-09-09 4-Antibody AG Isolation and identification of antigen- or ligand-specific binding proteins
WO2009114815A1 (en) 2008-03-13 2009-09-17 Dyax Corp Libraries of genetic packages comprising novel hc cdr3 designs
CA3049612C (en) 2008-04-24 2023-01-10 Dyax Corp. Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs
WO2009131702A2 (en) 2008-04-25 2009-10-29 Dyax Corp. Antibodies against fcrn and use thereof
KR20110014607A (en) 2008-04-29 2011-02-11 아보트 러보러터리즈 Dual Variable Domain Immunoglobulins and Uses thereof
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
AU2009245354C1 (en) 2008-05-09 2016-05-19 AbbVie Deutschland GmbH & Co. KG Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof
KR20110016958A (en) 2008-06-03 2011-02-18 아보트 러보러터리즈 Dual Variable Domain Immunoglobulins and Uses thereof
MX2010013236A (en) 2008-06-03 2011-02-24 Abbott Lab Dual variable domain immunoglobulins and uses thereof.
WO2010006059A1 (en) 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 binding proteins and uses thereof
CN102149825B (en) 2008-07-08 2015-07-22 Abbvie公司 Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
US8067339B2 (en) 2008-07-09 2011-11-29 Merck Sharp & Dohme Corp. Surface display of whole antibodies in eukaryotes
JP2012504424A (en) 2008-10-03 2012-02-23 ゾーマ テクノロジー リミテッド Triple tag sequences and how to use them
EP2349329A4 (en) 2008-10-14 2012-10-31 Dyax Corp Use of igf-ii/igf-iie binding for the treatment and prevention of systemic sclerosis associated pulmonary fibrosis
JP2012510821A (en) * 2008-12-04 2012-05-17 アボット・ラボラトリーズ Dual variable domain immunoglobulins and uses thereof
CA2746840A1 (en) 2008-12-16 2010-06-24 Novartis Ag Yeast display systems
WO2010079189A1 (en) * 2009-01-09 2010-07-15 Morphosys Ag Display vectors and methods and uses thereof
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
US8383778B2 (en) * 2009-01-29 2013-02-26 Abbvie Inc. IL-1 binding proteins
US8030026B2 (en) * 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
SG173705A1 (en) 2009-03-05 2011-09-29 Abbott Lab Il-17 binding proteins
PT2435568E (en) 2009-05-29 2014-10-08 Morphosys Ag Collection of synthetic antibodies for treating disease
CN105131112A (en) 2009-08-29 2015-12-09 Abbvie公司 Therapeutic dll4 binding proteins
MX2012002651A (en) 2009-09-01 2012-05-22 Abbott Lab Dual variable domain immunoglobulins and uses thereof.
WO2011032181A2 (en) 2009-09-14 2011-03-17 Dyax Corp. Libraries of genetic packages comprising novel hc cdr3 designs
WO2011035205A2 (en) 2009-09-18 2011-03-24 Calmune Corporation Antibodies against candida, collections thereof and methods of use
JP5990102B2 (en) 2009-09-29 2016-09-07 ユニフェルシテイト ヘント Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose
PH12012500691A1 (en) 2009-10-15 2012-11-12 Abbott Lab Dual variable domain immunoglobulins and uses thereof
UY32979A (en) 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
WO2011053707A1 (en) 2009-10-31 2011-05-05 Abbott Laboratories Antibodies to receptor for advanced glycation end products (rage) and uses thereof
CA2780024A1 (en) 2009-11-11 2011-05-19 Gentian As Immunoassay for assessing related analytes of different origin
JP2013511272A (en) 2009-11-19 2013-04-04 オキシレイン ユーケー リミテッド Yeast strain producing mammalian-like complex N-glycans
CN102656190A (en) 2009-12-08 2012-09-05 雅培股份有限两合公司 Monoclonal antibodies against the RGM A protein for use in the treatment of retinal nerve fiber layer degeneration
PT3459564T (en) 2010-01-06 2022-01-31 Takeda Pharmaceuticals Co Plasma kallikrein binding proteins
US20130096281A1 (en) * 2010-01-21 2013-04-18 Oxyrane Uk Limited Methods and compositions for displaying a polypeptide on a yeast cell surface
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
EP2542582A4 (en) 2010-03-02 2013-12-04 Abbvie Inc Therapeutic dll4 binding proteins
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
AU2011252883B2 (en) 2010-05-14 2015-09-10 Abbvie Inc. IL-1 binding proteins
US20120009196A1 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (en) 2010-07-09 2012-01-31 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
DK2593594T3 (en) 2010-07-16 2017-12-11 Adimab Llc ANTIBODY LIBRARIES
AR082461A1 (en) 2010-08-03 2012-12-12 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
CA2808187A1 (en) 2010-08-14 2012-02-23 Abbvie Inc. Amyloid-beta binding proteins
HUE058226T2 (en) 2010-08-19 2022-07-28 Zoetis Belgium S A Anti-ngf antibodies and their use
CA2809433A1 (en) 2010-08-26 2012-03-01 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US9347050B2 (en) 2010-09-29 2016-05-24 Oxyrane Uk Limited Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated N-glycans and methods of facilitating mammalian cellular uptake of glycoproteins
WO2012042387A2 (en) 2010-09-29 2012-04-05 Oxyrane Uk Limited De-mannosylation of phosphorylated n-glycans
WO2012052391A1 (en) 2010-10-19 2012-04-26 Glaxo Group Limited Polypeptide with jmjd3 catalytic activity
JP6253986B2 (en) 2010-11-19 2017-12-27 モルフォシス・アーゲー Collection and its usage
MY163368A (en) 2010-12-21 2017-09-15 Abbvie Inc Il-1-alpha and -beta bispecific dual variable domain immunoglobulins and their use
TW201307388A (en) 2010-12-21 2013-02-16 Abbott Lab IL-1 binding proteins
PH12013502378A1 (en) 2011-06-02 2014-01-06 Dyax Corp Fc RECEPTOR BINDING PROTEINS
RU2640025C2 (en) 2011-07-13 2017-12-25 Эббви Инк. Methods and compositions for asthma treatment using antibodies against il-13
IN2014CN03936A (en) 2011-10-24 2015-09-04 Abbvie Inc
CA2853258A1 (en) 2011-10-24 2013-05-02 Abbvie Inc. Immunobinders directed against sclerostin
SG11201402619VA (en) 2011-11-23 2014-10-30 Igenica Biotherapeutics Inc Anti-cd98 antibodies and methods of use thereof
CA3204283A1 (en) 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
EP2791175A2 (en) 2011-12-14 2014-10-22 Abbvie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
BR112014015851A2 (en) 2011-12-30 2019-09-24 Abbvie Inc double specific binding proteins directed against il-13 and / or il-17
CA2857967C (en) 2012-01-27 2020-08-11 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration
CA2867237C (en) 2012-03-15 2024-01-02 Wouter Vervecken Methods and materials for treatment of pompe's disease
EP2644693A1 (en) * 2012-03-29 2013-10-02 IP Bewertungs AG (IPB) Biologically active polypertide expressed on the surface of a cell
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
TW201402608A (en) 2012-07-12 2014-01-16 Abbvie Inc IL-1 binding proteins
CA2887129A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
UY35110A (en) 2012-11-01 2014-05-30 Abbvie Inc ANTI-VEGF / DLL4 DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES OF THE SAME
TWI745610B (en) 2012-11-14 2021-11-11 美商再生元醫藥公司 Recombinant cell surface capture proteins
US9550986B2 (en) 2012-12-21 2017-01-24 Abbvie Inc. High-throughput antibody humanization
BR112015023355A8 (en) 2013-03-14 2018-01-30 Abbott Lab hcv ns3 recombinant antigens and mutants thereof for enhanced antibody detection.
CN105228649B (en) 2013-03-14 2019-01-18 雅培制药有限公司 HCV Ag-Ab combination measurement is with method and used in composition therein
DK2968304T3 (en) 2013-03-14 2019-01-28 Univ Columbia 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE.
JP6739329B2 (en) 2013-03-14 2020-08-12 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ HCV core lipid binding domain monoclonal antibody
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
US9062108B2 (en) 2013-03-15 2015-06-23 Abbvie Inc. Dual specific binding proteins directed against IL-1 and/or IL-17
JP6581572B2 (en) 2013-06-07 2019-09-25 デューク ユニバーシティ Complement factor H inhibitor
WO2015090230A1 (en) 2013-12-19 2015-06-25 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
RU2701434C2 (en) 2014-01-24 2019-09-26 Нгм Биофармасьютикалс, Инк. Binding proteins and methods for use thereof
JP6814634B2 (en) 2014-02-05 2021-01-20 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. Methods for screening, selecting, and identifying cytotoxic recombinant polypeptides based on a temporary reduction in revolving toxicity
US10816554B2 (en) 2014-04-04 2020-10-27 The Board Of Trustees Of The Leland Stanford Junior University Ligand discovery for T cell receptors
BR112017001242A2 (en) 2014-07-21 2017-12-05 Novartis Ag cancer treatment using a cd33 chimeric antigen receptor
CA2958200A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
RU2020117196A (en) 2014-08-19 2020-10-15 Новартис Аг CHIMERIC ANTIGENIC RECEPTOR (CAR) AGAINST CD123 FOR USE IN THE TREATMENT OF MALIGNANT TUMORS
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
WO2016196314A1 (en) 2015-05-29 2016-12-08 Abbvie Inc. Anti-cd40 antibodies and uses thereof
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors
KR20180054824A (en) 2015-09-29 2018-05-24 셀진 코포레이션 PD-1 binding protein and method of use thereof
US11384354B2 (en) * 2015-12-21 2022-07-12 Zumutor Biologics Inc. Method of generating an antibody naïve library, said library and application(s) thereof
RU2683549C1 (en) * 2015-12-29 2019-03-28 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) SYSTEM FOR EXPRESSION OF FAB-FRAGMENTS OF ANTIBODIES IN METHYLOTROPHIC YEAST PICHIAPASTORIS, ON THE BASIS OF RECOMBINANT PLASMID DNA Ab-HCh-HIS/pPICZ_α_A AND Ab-LCh-LAMBDA/pPICZα_A, INTENDED TO CLONE VARIABLE DOMAINS OF ANTIBODY HEAVY AND LIGHT CHAINS, RESPECTIVELY
US20170205421A1 (en) * 2016-01-15 2017-07-20 University Of Washington Synthetic yeast agglutination
US10988759B2 (en) 2016-01-15 2021-04-27 University Of Washington High throughput protein-protein interaction screening in yeast liquid culture
CA3030837A1 (en) 2016-07-15 2018-01-18 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
EP3515944A4 (en) 2016-09-19 2020-05-06 Celgene Corporation Methods of treating immune disorders using pd-1 binding proteins
US10766958B2 (en) 2016-09-19 2020-09-08 Celgene Corporation Methods of treating vitiligo using PD-1 binding antibodies
BR112019006706A2 (en) 2016-10-03 2019-06-25 Abbott Lab improved methods for assessing gfap status in patient samples
AR110676A1 (en) 2016-10-07 2019-04-24 Novartis Ag TREATMENT OF CANCER USING CHEMERIC ANTIGENS RECEPTORS
US10815525B2 (en) 2016-12-22 2020-10-27 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10550429B2 (en) 2016-12-22 2020-02-04 10X Genomics, Inc. Methods and systems for processing polynucleotides
WO2018130660A1 (en) 2017-01-13 2018-07-19 Academia Sinica Reloadable hydrogel system for treating myocardial infarction
TWI659751B (en) 2017-01-13 2019-05-21 中央研究院 Improved reloadable hydrogel system for treating brain conditions
WO2018175942A1 (en) 2017-03-23 2018-09-27 Abbott Laboratories Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
CA3053409A1 (en) 2017-04-15 2018-10-18 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
AU2018256845B2 (en) 2017-04-28 2024-03-14 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
EP3631465A1 (en) 2017-05-25 2020-04-08 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
AU2018275236B2 (en) 2017-05-30 2024-11-07 Abbott Laboratories Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I
EP3649474A1 (en) 2017-07-03 2020-05-13 Abbott Laboratories Improved methods for measuring ubiquitin carboxy-terminal hydrolase l1 levels in blood
WO2019012141A1 (en) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Improved dual specificity polypeptide molecule
CA3078460A1 (en) 2017-10-04 2019-04-11 Opko Pharmaceuticals, Llc Articles and methods directed to personalized therapy of cancer
CN110892266A (en) 2017-12-09 2020-03-17 雅培实验室 Methods of using a combination of GFAP and UCH-L1 to aid in the diagnosis and evaluation of traumatic brain injury in human subjects
BR112019028254A2 (en) 2017-12-09 2020-07-14 Abbott Laboratories methods to assist in the diagnosis and evaluation of a patient who has suffered an orthopedic injury and who has suffered or may have suffered a head injury, such as a mild traumatic brain injury (lct), using glial fibrillar acid protein (gfap) and / or the carboxy-terminal hydrolase of ubiquitin l1 (uch-l1)
SG11202007686VA (en) 2018-02-12 2020-09-29 10X Genomics Inc Methods characterizing multiple analytes from individual cells or cell populations
AU2019234213A1 (en) 2018-03-12 2020-09-03 Zoetis Services Llc Anti-NGF antibodies and methods thereof
WO2019217758A1 (en) 2018-05-10 2019-11-14 10X Genomics, Inc. Methods and systems for molecular library generation
AU2019269628A1 (en) * 2018-05-17 2020-12-03 The Board Of Trustees Of The Leland Stanford Junior University Receptor inhibition by phosphatase recruitment
AU2019345157A1 (en) 2018-09-20 2021-12-23 Vir Biotechnology, Inc. Engineered microorganisms and methods of making and using same
BR112021005585A2 (en) 2018-09-27 2021-06-29 Celgene Corporation Sirpa binding proteins and methods of using them
US20210380675A1 (en) 2018-09-28 2021-12-09 Kyowa Kirin Co., Ltd. Il-36 antibodies and uses thereof
CN114144190A (en) 2019-01-23 2022-03-04 纽约大学 Antibodies specific for the delta 1 chain of T cell receptors
BR112021021261A2 (en) * 2019-04-22 2021-12-21 Ddbio Co Ltd Shang Hai Method for producing a phage library that displays an antibody or antibody fragment, phage library and method for selecting an antibody or antibody fragment
IL295387A (en) 2020-02-05 2022-10-01 Larimar Therapeutics Inc Peptide-binding proteins and their uses
CA3175523A1 (en) 2020-04-13 2021-10-21 Antti Virtanen Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample
CA3173351C (en) 2020-05-11 2024-01-02 David Younger High-throughput screening methods to identify small molecule targets
EP4158015A1 (en) 2020-06-01 2023-04-05 A-Alpha Bio, Inc. Methods for characterizing and engineering protein-protein interactions
WO2022031576A1 (en) 2020-08-03 2022-02-10 Janssen Biotech, Inc. Materials and methods for multidirectional biotransportation in virotherapeutics
US20220043000A1 (en) 2020-08-04 2022-02-10 Abbott Laboratories Methods and kits for detecting sars-cov-2 protein in a sample
CN112646833A (en) 2020-11-05 2021-04-13 杭州阿诺生物医药科技有限公司 Design and construction of fully human antibody yeast display technology
CA3198161A1 (en) 2020-12-01 2022-06-09 Beth MCQUISTON Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
WO2023102384A1 (en) 2021-11-30 2023-06-08 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
EP4271998A1 (en) 2020-12-30 2023-11-08 Abbott Laboratories Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
EP4271482A2 (en) 2020-12-31 2023-11-08 Alamar Biosciences, Inc. Binder molecules with high affinity and/ or specificity and methods of making and use thereof
KR20240004935A (en) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Antigen-binding protein that specifically binds to PRAME
CA3216320A1 (en) 2021-05-18 2022-11-24 Abbott Laboratories Methods of evaluating brain injury in a pediatric subject
US20240118279A1 (en) 2021-06-14 2024-04-11 Abbott Laboratories Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
AU2022339759A1 (en) 2021-08-31 2024-03-07 Abbott Laboratories Methods and systems of diagnosing brain injury
CN118715440A (en) 2021-08-31 2024-09-27 雅培实验室 Method and system for diagnosing brain injury
EP4144898A1 (en) * 2021-09-07 2023-03-08 New/era/mabs GmbH Method for selecting or screening antibodies from an antibody library
JP2024538608A (en) 2021-09-30 2024-10-23 アボット・ラボラトリーズ Method and system for diagnosing brain damage
WO2023114978A1 (en) 2021-12-17 2023-06-22 Abbott Laboratories Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
AR128222A1 (en) 2022-01-07 2024-04-10 Johnson & Johnson Entpr Innovation Inc IL-1b BINDING PROTEIN MATERIALS AND METHODS
EP4473311A1 (en) 2022-02-04 2024-12-11 Abbott Laboratories Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
ES2955461B2 (en) * 2022-05-24 2024-12-27 Univ Valencia Politecnica YEAST AND PLASMID FOR SURFACE PROTEIN DISPLAY
WO2024006876A1 (en) 2022-06-29 2024-01-04 Abbott Laboratories Magnetic point-of-care systems and assays for determining gfap in biological samples
CN119948051A (en) 2022-07-15 2025-05-06 詹森生物科技公司 Materials and methods for improving bioengineered pairing of antigen binding variable regions
AU2023342055A1 (en) 2022-09-15 2025-03-13 Abbott Laboratories Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
WO2024211475A1 (en) 2023-04-04 2024-10-10 Abbott Laboratories Use of biomarkers to determine whether a subject has sustained, may have sustained or is suspected of sustaining a subacute acquired brain injury (abi)
WO2024226971A1 (en) 2023-04-28 2024-10-31 Abbott Point Of Care Inc. Improved assays, cartridges, and kits for detection of biomarkers, including brain injury biomarkers

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
GB2183661B (en) * 1985-03-30 1989-06-28 Marc Ballivet Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL84285A (en) * 1986-10-27 1993-03-15 Int Genetic Engineering Chimeric antibody with specificity to human tumor antigen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE69233750D1 (en) * 1991-04-10 2009-01-02 Scripps Research Inst Libraries of heterodimeric receptors using phagemids
AU685057B2 (en) 1992-07-08 1998-01-15 Unilever Plc Process for immobilizing enzymes to the cell wall of a microbial cell by producing a fusion protein
AU6139794A (en) 1993-02-10 1994-08-29 Unilever Plc Immobilized proteins with specific binding capacities and their use in processes and products
ATE243745T1 (en) * 1994-01-31 2003-07-15 Univ Boston LIBRARIES OF POLYCLONAL ANTIBODIES
US5643745A (en) * 1994-02-03 1997-07-01 University Of Hawaii Heterologous dimeric proteins produced in heterokaryons
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6117679A (en) * 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5695941A (en) * 1994-06-22 1997-12-09 The General Hospital Corporation Interaction trap systems for analysis of protein networks
ES2181900T3 (en) * 1995-06-07 2003-03-01 Invitrogen Corp RECOMBINANT CLONING IN VITRO USANTO RECOMBINATION SITES BY GENETIC ENGINEERING.
US20010041333A1 (en) 1997-06-16 2001-11-15 Short Jay M. High throughput screening for a bioactivity or biomolecule
US6300065B1 (en) * 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6696251B1 (en) 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US5895941A (en) * 1996-07-01 1999-04-20 Mitsubishi Denki Kabushiki Kaisha Field effect transistor with electrode portions under T-shaped gate structure
US6461863B1 (en) * 1996-08-16 2002-10-08 University Of Wyoming Modifying insect cell gylcosylation pathways with baculovirus expression vectors
US5869250A (en) 1996-12-02 1999-02-09 The University Of North Carolina At Chapel Hill Method for the identification of peptides that recognize specific DNA sequences
US5948653A (en) * 1997-03-21 1999-09-07 Pati; Sushma Sequence alterations using homologous recombination
US6207442B1 (en) * 1997-10-16 2001-03-27 Zymogenetics, Inc. Plasmid construction by homologous recombination
AU3587599A (en) 1997-11-28 1999-06-16 Invitrogen Corporation Single chain monoclonal antibody fusion reagents that regulate transcript ion in vivo
JP4786793B2 (en) 1998-03-30 2011-10-05 ノースウエスト バイオセラピューティクス，インコーポレイティド Therapeutic and diagnostic applications based on the role of CXCR-4 gene in tumorigenesis
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
US6867348B1 (en) 1999-12-16 2005-03-15 Xenogen Corporation Methods and compositions for screening for angiogenesis modulating compounds
WO2001079229A2 (en) 2000-04-13 2001-10-25 Genaissance Pharmaceuticals, Inc. Haplotypes of the cxcr4 gene
WO2001083796A2 (en) 2000-05-03 2001-11-08 University Of Washington Adenoviral vectors for tumor specific gene expression and uses thereof
US6410271B1 (en) 2000-06-23 2002-06-25 Genetastix Corporation Generation of highly diverse library of expression vectors via homologous recombination in yeast
US6406863B1 (en) 2000-06-23 2002-06-18 Genetastix Corporation High throughput generation and screening of fully human antibody repertoire in yeast
US6410246B1 (en) 2000-06-23 2002-06-25 Genetastix Corporation Highly diverse library of yeast expression vectors
US20020026653A1 (en) 2000-07-10 2002-02-28 Allen Keith D. Transgenic mice containing serine protease gene disruptions
US6610472B1 (en) 2000-10-31 2003-08-26 Genetastix Corporation Assembly and screening of highly complex and fully human antibody repertoire in yeast
US7138496B2 (en) 2002-02-08 2006-11-21 Genetastix Corporation Human monoclonal antibodies against human CXCR4
US7005503B2 (en) 2002-02-08 2006-02-28 Genetastix Corporation Human monoclonal antibody against coreceptors for human immunodeficiency virus
US20030165988A1 (en) 2002-02-08 2003-09-04 Shaobing Hua High throughput generation of human monoclonal antibody against peptide fragments derived from membrane proteins
WO2002046400A2 (en) 2000-12-08 2002-06-13 The Board Of Trustees Of The University Of Illinois Mutated class ii major histocompatibility proteins
JP4234999B2 (en) 2001-04-06 2009-03-04 トマス ジェファソン ユニバーシティ Multimer formation of HIV-1 VIF protein as a therapeutic target
ES2405551T3 (en) 2001-10-01 2013-05-31 Dyax Corporation Multicatenary eukaryotic presentation vectors and uses thereof
US20030232395A1 (en) 2002-06-14 2003-12-18 Dyax Corporation Recombination of nucleic acid library members
JP2012503490A (en) 2008-09-26 2012-02-09 ワイス・エルエルシー Single chain antibody library design

Also Published As

Publication number Publication date
AU2002330162B2 (en) 2008-08-07
US9068980B2 (en) 2015-06-30
US20110281761A1 (en) 2011-11-17
AU2008203340A1 (en) 2008-08-14
US20110190159A1 (en) 2011-08-04
EP2093286A1 (en) 2009-08-26
CA2462113C (en) 2013-01-29
US9005927B2 (en) 2015-04-14
DK2093286T3 (en) 2013-05-13
US9556428B2 (en) 2017-01-31
AU2008203340B2 (en) 2012-01-19
CA2462113A1 (en) 2003-04-10
US10577599B2 (en) 2020-03-03
US9012181B2 (en) 2015-04-21
EP1438400B1 (en) 2009-06-17
DK1438400T3 (en) 2009-10-05
EP2093286B1 (en) 2013-02-27
US9116149B2 (en) 2015-08-25
US20190211322A1 (en) 2019-07-11
US9040258B2 (en) 2015-05-26
JP4578098B2 (en) 2010-11-10
ES2327905T3 (en) 2009-11-05
ES2405551T3 (en) 2013-05-31
JP5111558B2 (en) 2013-01-09
EP1438400A1 (en) 2004-07-21
JP2005504541A (en) 2005-02-17
US20110281360A1 (en) 2011-11-17
US9034601B2 (en) 2015-05-19
US20030186374A1 (en) 2003-10-02
US20110009280A1 (en) 2011-01-13
US10059936B2 (en) 2018-08-28
US20110287971A1 (en) 2011-11-24
US20170314012A1 (en) 2017-11-02
JP2010227114A (en) 2010-10-14
EP1438400A4 (en) 2006-01-04
US20160040157A1 (en) 2016-02-11
DE60232672D1 (en) 2009-07-30
PT1438400E (en) 2009-09-10
WO2003029456A1 (en) 2003-04-10
US20130331289A1 (en) 2013-12-12

Similar Documents

Publication Publication Date Title
ATE434040T1 (en) MULTI-CHAIN EUKARYONTIC DISPLAY VECTORS AND USES THEREOF
ES2176484T3 (en) PROTEIN BANKS / (POLI) PEPTIDES.
DK0556345T3 (en) Retroviral vectors suitable for gene therapy
HUP0402162A2 (en) Specific binding agents of human angiopoietin-2
DK2014678T3 (en) KDR peptides and vaccines containing them
HK1156660A1 (en) Focused libraries of genetic packages
DE69823046D1 (en) PRACTICAL IN VITRO SIALYLATION OF RECOMBINANT GLYC PROTEINS
DE69733247D1 (en) HUMANIZED GREEN FLUORESCENCE PROTEIN AND METHODS
DK1149905T3 (en) Methods and Preparation for Polypeptide Technology
WO2005017149A8 (en) Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
GB9911047D0 (en) Assay method and means
HK1030613A1 (en) Chimeric polypeptide comprising the fragment b of shiga toxin and peptides of therapeutic interest
NO910982L (en) URATOXYDASE-ACTIVE PROTEIN, RECOMBINANT GENE CODING IT, EXPRESSION VECTOR, MICROORGANISMS AND TRANSFORMER CELLS.
ATE333520T1 (en) NOVEL POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNALPHA-21 GENE
Lucas-Lenard et al. 2. Protein Synthesis—Peptide Chain Elongation
NO20014537L (en) AKT nucleic acids, polypeptides and their use
HRP20050024A2 (en) Pegylated t20 polypeptide
IS2889B (en) Bv8 nucleic acids and polypeptides with mitosis-causing activity
DE60233756D1 (en) VECTOR-ORGANIZED ORGANIC TRANSFECTION
EP0990703A4 (en) Novel polypeptide, dna encoding the same and use thereof
DE69735039D1 (en) Acetylhydrolase of platelet activating factor, and corresponding gene
ATE514716T1 (en) FRAGMENTS OF TOXIN-RELATED ANTIBODIES, WITH ANTIMICROBIAL AND ANTIVIRAL ACTIVITY
ATE417066T1 (en) MODIFIED CDNA FOR HIGH EXPRESSION LEVELS OF FACTOR VIII AND ITS DERIVATIVES
Zahn How Insulin Came from Heidelberg to Aachen and Why it Took Five Years
DK0870050T3 (en) Virus expressing a toxic protein and producer cell lines

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1438400

Country of ref document: EP

OSZAR »